Delgado-Tirado, Santiago
Amarnani, Dhanesh
Zhao, Guannan
Rossin, Elizabeth J.
Eliott, Dean
Miller, John B.
Greene, Whitney A.
Ramos, Leslie
Arevalo-Alquichire, Said
Leyton-Cifuentes, David
Gonzalez-Buendia, Lucia
Isaacs-Bernal, Daniela
Whitmore, Hannah A. B.
Chmielewska, Natalia
Duffy, Brandon V.
Kim, Eric
Wang, Heuy-Ching
Ruiz-Moreno, Jose M.
Kim, Leo A.
Arboleda-Velasquez, Joseph F.
Funding for this research was provided by:
Fundacion Alfonso Martin Escudero
Departamento Administrativo de Ciencia, Tecnología e Innovación
National Eye Institute (R01EY027739)
E. Matilda Ziegler Foundation for the Blind
Karl Kirchgessner Foundation
U.S. Department of Defense (W81XWH-17-2-0006)
Article History
Received: 9 March 2020
Accepted: 9 November 2020
First Online: 30 November 2020
Competing interests
: The Schepens Eye Research Institute of Mass. Eye and Ear has filed patents for the use of RUNX1 as a treatment for PVR listing L.A.K, J.F.A.-V., D.A. and D.E. as inventors, and a patent for the use of nanoemulsion formulations of RUNX1 inhibitors listing L.A.K. and J.F.A.-V. as inventors. D.E. has an equity interest in Aldeyra Therapeutics Inc. The rest of the co-authors declare they have no competing interests.